共 104 条
[1]
Lang A.E., Lozano A.M., Parkinson’s disease. First of two parts, N Engl J Med, 339, 15, pp. 1044-1053, (1998)
[2]
Dauer W., Przedborski S., Parkinson’s disease: mechanisms and models, Neuron, 39, 6, pp. 889-909, (2003)
[3]
Yuan H., Zhang Z.W., Liang L.W., Shen Q., Wang X.D., Ren S.M., Ma H.J., Jiao S.J., Liu P., Treatment strategies for Parkinson’s disease, Neurosci Bull, 26, 1, pp. 66-76, (2010)
[4]
Liu Y., Yue F., Tang R., Tao G., Pan X., Zhu L., Kung H.F., Chan P., Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133), Neurosci Bull, 30, 3, pp. 409-416, (2014)
[5]
Hirsch E.C., Hunot S., Neuroinflammation in Parkinson’s disease: a target for neuroprotection?, Lancet Neurol, 8, 4, pp. 382-397, (2009)
[6]
Hornykiewicz O., Kish S.J., Biochemical pathophysiology of Parkinson’s disease, Parkinson’s disease, pp. 19-34, (1987)
[7]
Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K., Stages in the development of Parkinson’s disease-related pathology, Cell Tissue Res, 318, 1, pp. 121-134, (2004)
[8]
Le W., Sayana P., Jankovic J., Animal models of Parkinson’s disease: a gateway to therapeutics?, Neurotherapeutics, 11, 1, pp. 92-110, (2014)
[9]
Blandini F., Armentero M.T., Animal models of Parkinson’s disease, FEBS J, 279, 7, pp. 1156-1166, (2012)
[10]
Tieu K., A guide to neurotoxic animal models of Parkinson’s disease, Cold Spring Harb Perspect Med, 1, 1, (2011)